Brief: Tempest Therapeutics Says Nicholas Maestas Resigns As CFO Effective June 5
04/06/2026 22:14
BRIEF-Tempest Therapeutics Says Nicholas Maestas Resigns As CFO Effective June 5 June 4 (Reuters) - Tempest Therapeutics Inc TPST.O:
TEMPEST THERAPEUTICS - NICHOLAS MAESTAS RESIGNS AS CFO EFFECTIVE JUNE 5, 2026 - SEC FILING
TEMPEST THERAPEUTICS - APPOINTS JUSTIN TROJANOWSKI AS PRINCIPAL FINANCIAL OFFICER EFFECTIVE JUNE 5, 2026 - SEC FILING
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T